Insmed Halts Sinus Treatment, Acquires New Drug Candidate
Insmed discontinues brensocatib for chronic sinus disease after failed trial but adds promising antibody therapy INS1148 to its pipeline for lung and immune conditions.
/ 907 items
#Healthcare↓
Vistagen Stock Plunges After Social Anxiety Drug Fails Phase 3 Trial
Vistagen Therapeutics stock crashes after fasedienol, its experimental nasal spray for social anxiety disorder, fails to meet primary endpoints in Phase 3 PALISADE-3 trial.
Vyne Therapeutics to Merge With Yarrow Bioscience in All-Stock Deal
Vyne Therapeutics and Yarrow Bioscience plan an all-stock merger to focus on YB-101, a new treatment for Graves’ disease and thyroid eye disease.
Compugen Secures $90M Deal with AstraZeneca
Compugen monetizes cancer drug royalties to AstraZeneca (AZN) for up to $90 million, extending operations until 2029 while retaining majority future earnings.
JPMorgan Turns Bullish on Recursion Pharmaceuticals
JPMorgan upgrades Recursion Pharmaceuticals to Overweight, raises price target to $11, and highlights blockbuster potential for REC-4881 and promising early cancer data.
Peanut Allergy Patch Shows 47% Success Rate in Children
DBV Technologies' (DBVT) VIASKIN Peanut patch shows significant success in treating peanut allergies in children aged 4-7, with nearly half of participants responding positively after one year.